SG162829A1 - Humanised antibodies specific for nogo-a and pharmaceutical uses thereof - Google Patents

Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Info

Publication number
SG162829A1
SG162829A1 SG201004551-6A SG2010045516A SG162829A1 SG 162829 A1 SG162829 A1 SG 162829A1 SG 2010045516 A SG2010045516 A SG 2010045516A SG 162829 A1 SG162829 A1 SG 162829A1
Authority
SG
Singapore
Prior art keywords
nogo
antibodies specific
pharmaceutical uses
humanised antibodies
antibodies
Prior art date
Application number
SG201004551-6A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Paul Andrew Hamblin
Farhana Hussain
Alan Peter Lewis
Ruth Mcadam
Rabinder Prinjha
Paul Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG162829A1 publication Critical patent/SG162829A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201004551-6A 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and pharmaceutical uses thereof SG162829A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins

Publications (1)

Publication Number Publication Date
SG162829A1 true SG162829A1 (en) 2010-07-29

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004551-6A SG162829A1 (en) 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Country Status (21)

Country Link
EP (1) EP1899377B1 (pl)
JP (1) JP2009500363A (pl)
KR (1) KR20080030960A (pl)
AU (1) AU2006265276B2 (pl)
BR (1) BRPI0612734A2 (pl)
CA (1) CA2614076A1 (pl)
CR (1) CR9623A (pl)
CY (1) CY1113310T1 (pl)
DK (1) DK1899377T3 (pl)
EA (1) EA014291B1 (pl)
ES (1) ES2391902T3 (pl)
HR (1) HRP20120851T1 (pl)
IL (1) IL188282A (pl)
MA (1) MA29625B1 (pl)
NO (1) NO20076663L (pl)
NZ (1) NZ564567A (pl)
PL (1) PL1899377T3 (pl)
PT (1) PT1899377E (pl)
SG (1) SG162829A1 (pl)
SI (1) SI1899377T1 (pl)
WO (1) WO2007003421A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
HRP20130699T1 (hr) * 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins

Also Published As

Publication number Publication date
SI1899377T1 (sl) 2012-12-31
NO20076663L (no) 2008-02-27
NZ564567A (en) 2010-09-30
CA2614076A1 (en) 2007-01-11
WO2007003421A2 (en) 2007-01-11
WO2007003421A3 (en) 2007-04-12
AU2006265276A1 (en) 2007-01-11
CY1113310T1 (el) 2016-04-13
EP1899377B1 (en) 2012-08-22
BRPI0612734A2 (pt) 2010-11-30
KR20080030960A (ko) 2008-04-07
PL1899377T3 (pl) 2013-01-31
AU2006265276B2 (en) 2011-10-13
IL188282A (en) 2011-04-28
ES2391902T3 (es) 2012-11-30
HRP20120851T1 (hr) 2012-11-30
DK1899377T3 (da) 2012-11-12
MA29625B1 (fr) 2008-07-01
EA014291B1 (ru) 2010-10-29
EP1899377A2 (en) 2008-03-19
HK1115598A1 (en) 2008-12-05
JP2009500363A (ja) 2009-01-08
IL188282A0 (en) 2008-04-13
CR9623A (es) 2008-04-10
EA200702634A1 (ru) 2008-06-30
PT1899377E (pt) 2012-11-20

Similar Documents

Publication Publication Date Title
MY144612A (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2010003574A (es) Anticuerpos il-23.
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
TW200709817A (en) Platform antibody compositions
JO2576B1 (en) Antibodies
UA92505C2 (ru) Композиции на основе антитела против cd3
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
TW200740844A (en) Novel MAdCAM antibodies
IL185754A0 (en) Novel anti-plgf antibody
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY157661A (en) Bendamustine pharmaceutical compositions
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
MX2009003981A (es) Agentes moduladores del receptor de calcio.
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.
WO2007007159A3 (en) Anti-madcam antibodies to treat uterine disorders